Descrizione del progetto
Avanzamento dei saggi di scoperta di farmaci
La scoperta di bersagli terapeutici è un passaggio chiave nella pipeline di scoperta di farmaci, in cui lo screening ad alto rendimento (HTS, High-Throughput Screening) di sostanze chimiche viene valutato in vari processi biologici. Lo scopo del progetto HTS MALDI-TOF MDD, finanziato dall’UE, è quello di incorporare la spettrometria di massa a tempo di volo con desorbimento/ionizzazione laser assistito da matrice (MALDI-TOF) nei saggi di metabolomica cellulare. Il piano è quello di studiare come i farmaci influenzano le diverse vie metaboliche e contemporaneamente mappare il profilo metabolico della cellula. Utilizzando un modello cellulare di fibrosi polmonare, i ricercatori valuteranno se determinati metaboliti possono servire come biomarcatori per la diagnosi delle malattie, nonché come lettura in saggi di scoperta di farmaci.
Obiettivo
Discovery for drug targets is a key step within the process of drug development, and is the corner stone in the pharmaceutical industry. This is mostly achieved by high-throughput screening (HTS) approaches in which a large number of chemical substances are assayed for a specific effect or activity in diverse areas of biology. Mass spectrometry (MS) has become a widely adopted tool in this field as it offers the possibility to simultaneously track molecules in a label-free manner, provides excellent signal to noise, reproducibility, assay precision, and a significantly reduced reagent cost when compared to fluorescence-based assays. Matrix-assisted laser/desorption ionisation time of flight (MALDI-TOF) is the most validated surface ionisation method for HTS approaches, but reported applications of this technology have been limited to in vitro assays with simple readouts and to peptide/protein-centric activity assays. To date, comprehensive and unbiased metabolomics based HTS approaches for cellular assays with MALDI-TOF have not been explored. The objective of this fellowship is to set up a MALDI-TOF based cellular assay for HTS metabolomics drug discovery in order to identify a set of metabolites to screen which will enable us to unbiasly and comprehensibly measure, in a HT manner, how drugs affect different metabolic pathways while simultaneously mapping the metabolic profile of the cell. First, I will develop a robust protocol for the detection, identification, and quantification of ~50 small metabolites for cellular assays. Then, I will apply this protocol to track metabolites in a pulmonary fibrosis cellular model, as well as in fibrotic lung tissue sections using MS imaging. The goal is to compare a disease model with the control to see how drugs are affecting these metabolites, and to see if identified biomarkers can be used to identify disease in tissue samples. As a final validation step, I will implement this platform in Boehringer Ingelheim in Germany.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinatore
NE1 7RU Newcastle Upon Tyne
Regno Unito